Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Adenocarcinoma of the Gastroesophageal Junction”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00253370
What this trial is testing

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionMetastatic Gastric CancerAdvanced Unresectable Gastric Cancer
National Cancer Institute (NCI) 44
Testing effectiveness (Phase 2)UnknownNCT04263870
What this trial is testing

Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Who this might be right for
Gastroesophageal Junction AdenocarcinomaStomach AdenocarcinomaLocally Advanced Unresectable Gastric Adenocarcinoma+1 more
Sichuan University 36
Testing effectiveness (Phase 2)Study completedNCT00583674
What this trial is testing

Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma

Who this might be right for
Gastrointestinal Cancer
Amgen 171
Testing effectiveness (Phase 2)Study completedNCT00032123
What this trial is testing

Erlotinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

Who this might be right for
Esophageal CancerGastric Cancer
SWOG Cancer Research Network
Large-scale testing (Phase 3)Looking for participantsNCT05427383
What this trial is testing

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Who this might be right for
Stomach Cancer
Shanghai JMT-Bio Inc. 286
Testing effectiveness (Phase 2)Ended earlyNCT05311176
What this trial is testing

IMU-131 (HER-Vaxx) in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric Cancer (nextHERIZON)

Who this might be right for
Gastric CancerCancer of StomachGastric Adenocarcinoma+3 more
Imugene Limited 7
Large-scale testing (Phase 3)Active Not RecruitingNCT05078047
What this trial is testing

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Who this might be right for
Lung Cancer MetastaticRenal Cell CarcinomaHead and Neck Cancer+12 more
UNICANCER 646
Testing effectiveness (Phase 2)Looking for participantsNCT06121700
What this trial is testing

Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer

Who this might be right for
AdenocarcinomaStomach NeoplasmGastroesophageal-junction Cancer+6 more
Fudan University 55
Testing effectiveness (Phase 2)Study completedNCT00397904
What this trial is testing

Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin

Who this might be right for
Esophageal CancerGastric Cancer
Memorial Sloan Kettering Cancer Center 16
Large-scale testing (Phase 3)Study completedNCT01170663
What this trial is testing

Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma

Who this might be right for
Gastric Cancer
Eli Lilly and Company 665
Testing effectiveness (Phase 2)Study completedNCT01585987
What this trial is testing

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Who this might be right for
Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Bristol-Myers Squibb 143
Early research (Phase 1)Looking for participantsNCT06773312
What this trial is testing

BC001 in Combination with Sintilimab and XELOX in the Treatment of HER-2 Negative Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma.

Who this might be right for
Advanced or Metastatic Gastric CancerGastroesophageal Junction Adenocarcinoma
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. 80
Testing effectiveness (Phase 2)Looking for participantsNCT06415669
What this trial is testing

Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric/Gastroesophageal Junction Adenocarcinoma
The First Affiliated Hospital of Xiamen University 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT05476796
What this trial is testing

Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Who this might be right for
Gastric AdenocarcinomaEsophagus AdenocarcinomaGastroesophageal Junction Adenocarcinoma
UNICANCER 118
Testing effectiveness (Phase 2)Study completedNCT01896531
What this trial is testing

Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric Cancer
Genentech, Inc. 153
Large-scale testing (Phase 3)Looking for participantsNCT06841679
What this trial is testing

Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Beijing Biostar Pharmaceuticals Co., Ltd. 778
Testing effectiveness (Phase 2)Study completedNCT01612546
What this trial is testing

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery

Who this might be right for
Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the Stomach+11 more
City of Hope Medical Center 10
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06577376
What this trial is testing

A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction AdenocarcinomaExpressing Human Epidermal Growth Factor Receptor-2 (HER-2)Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past
Shanghai Runshi Pharmaceutical Technology Co., Ltd
Large-scale testing (Phase 3)Looking for participantsNCT06793917
What this trial is testing

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Cancer
Fujian Cancer Hospital 269
Large-scale testing (Phase 3)Looking for participantsNCT07362186
What this trial is testing

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
LaNova Medicines Limited 400
Next Page
252